For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
Trump’s State of the Union: A closer look at the claims
Last night, President Trump delivered a State of the Union address filled with optimism, applause lines, and bold claims about the country’s direction. There…
Citation
‘Just the beginning of enormous growth’: White House heralds strong jobs report
The Black Chronicle cited CEI’s expert on job growth in healthcare Senior Economist with the Competitive Enterprise Institute Ryan Young also interpreted the siloed…
Blog
FDA’s Moderna decision demonstrates how science and government are incompatible
Last week, the FDA announced that it would not be considering Moderna’s application for a new flu vaccine because the control group Moderna used…
Search Posts
Op-Eds
Sympathy for the Mosquito?
“Save Our Mosquitoes,” isn't a plea one expects to see these days with the mosquito-borne West Nile Virus killing hundreds and making thousands…
News Release
Soso R. Whaley Featured in The American Spectator
Click here to read full story. <?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> <?xml:namespace prefix =…
News Release
Enter and Win!
Name that film!<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> For a month, you’ve been reading about Soso’s…
News Release
Media Conference Call, Wed., May 5
Contact: Jody Clarke, 202.331.2252<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> Washington, DC, May 4, 2004—Her quest started…
Op-Eds
“I Love Humanity; It’s People I Can’t Stand”
This is part 2 of a two-part series. To read part 1, please click here.<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” />…
Op-Eds
Biotech’s Antagonists
This is part 1 of a two-part series. To read part 2, please click here.<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” />…